Oramed Pharmaceuticals Inc (ORMP) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $3.43
• Market Cap: $148.63M
• P/E Ratio: 3.73
• EPS: $1.00
• 52-Week High: $3.76
• 52-Week Low: $1.70

Market Sentiment

Oramed Pharmaceuticals Inc currently has a Bullish sentiment score of 0.21.

About Oramed Pharmaceuticals Inc

Oramed Pharmaceuticals Inc. is a groundbreaking biopharmaceutical company based in New York, focused on transforming diabetes management with its novel oral drug delivery systems. The company specializes in developing orally ingestible capsules for the administration of polypeptides, designed to improve patient adherence and outcomes in diabetes care. With a robust pipeline of innovative therapeutic solutions and a dedication to addressing critical unmet medical needs, Oramed is strategically...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Oramed Pharmaceuticals Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does ORMP pay dividends?

Oramed Pharmaceuticals Inc (ORMP) does not currently pay a regular dividend.

What is ORMP's P/E ratio?

Oramed Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 3.73.

What is ORMP's market cap?

Oramed Pharmaceuticals Inc (ORMP) has a market capitalization of $148.63M with a current stock price of $3.43.